ABVX

ABIVAX Société Anonyme is a healthcare company within the biotechnology industry. With a market capitalization of $9.72 billion and revenue of $5.31 million (TTM), the company operates on a relatively small scale with 67 employees. The financial performance of ABIVAX indicates significant losses, with net income at -$293.52 million (TTM) and EBITDA at -$217.95 million. The gross margin is 100.0%, while operating and profit margins are significantly negative at -12630.8% and 0.0%, respectively. Returns on equity and assets are also negative, standing at -106.4% and -31.7%, respectively. On the balance sheet side, cash reserves amount to $589.70 million, with debt totaling $73.99 million. ABIVAX's valuation metrics reveal a forward P/E ratio of -37.46 and an EV/EBITDA of -45.40, indicating substantial losses are expected in the future. The company does not pay dividends, as evidenced by a payout ratio of 0.0%. Revenue growth has contracted at a rate of -52.7% year-over-year (YoY), while earnings growth is not available.